| Zacks Company Profile for Akebia Therapeutics, Inc. (AKBA : NSDQ) |
|
|
| |
| • Company Description |
| Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Number of Employees: 181 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $3.98 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 4,117,879 shares |
| Shares Outstanding: 262.64 (millions) |
| Market Capitalization: $1,045.29 (millions) |
| Beta: 0.88 |
| 52 Week High: $4.08 |
| 52 Week Low: $1.07 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
9.04% |
4.96% |
| 12 Week |
93.20% |
62.51% |
| Year To Date |
109.47% |
96.17% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
245 FIRST STREET SUITE 1100
-
CAMBRIDGE,MA 02142
USA |
ph: 617-871-2098
fax: 617-871-2099 |
ir@akebia.com |
http://www.akebia.com |
|
|
| |
| • General Corporate Information |
Officers
John P. Butler - President and Chief Executive Officer
Adrian Adams - Chairperson
Erik J. Ostrowski - Senior Vice President; Chief Financial Officer and
Richard C. Malabre - Senior Vice President; Chief Accounting Officer
Ron Frieson - Director
|
|
Peer Information
Akebia Therapeutics, Inc. (GSAC)
Akebia Therapeutics, Inc. (CASI)
Akebia Therapeutics, Inc. (ALCD.)
Akebia Therapeutics, Inc. (OMNN)
Akebia Therapeutics, Inc. (CGPI.)
Akebia Therapeutics, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 00972D105
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
|
|
Share - Related Items
Shares Outstanding: 262.64
Most Recent Split Date: (:1)
Beta: 0.88
Market Capitalization: $1,045.29 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.02 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.05 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 4.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/14/25 |
|
|
|
| |
